Viva Biotech Investors Suspend Viva Shanghai Equity Repurchase Rights Until 2028

An announcement from Viva Biotech Holdings ( (HK:1873) ) is now available.

Viva Biotech Holdings announced that several institutional investors in its subsidiary Viva Shanghai—HLC SPV, Qingdao Hongyi, Daxue Investments, True Light P and Raed Capital Holdings 2 Ltd—have agreed to temporarily suspend their contractual right to require Viva Shanghai and related obligors to repurchase their equity interests if a qualified IPO or M&A is not completed by December 31, 2026. Under the undertaking, these investors will not enforce the repurchase obligation between December 31, 2026 and December 31, 2028, with all other terms of the shareholders’ agreement remaining in force, a move the company says reflects the investors’ confidence in Viva Shanghai’s business prospects and capital-raising plans amid current market conditions and provides the group with additional time and flexibility to execute its strategic options, with further updates to be announced as appropriate.

The most recent analyst rating on (HK:1873) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on Viva Biotech Holdings stock, see the HK:1873 Stock Forecast page.

More about Viva Biotech Holdings

Viva Biotech Holdings, incorporated in the Cayman Islands and listed in Hong Kong, operates through subsidiaries including Viva Shanghai, focusing on biotech-related businesses and capital-raising activities in the life sciences sector. The group attracts institutional investors to support the development and potential IPO or M&A transactions of its portfolio companies, positioning itself within the broader biotech and pharmaceutical services industry.

Average Trading Volume: 6,051,856

Technical Sentiment Signal: Sell

Current Market Cap: HK$3.72B

For detailed information about 1873 stock, go to TipRanks’ Stock Analysis page.